lorlatinib
- Generic Name
- lorlatinib
- Brand Names
- Lorbrena, Lorviqua
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19FN6O2
- CAS Number
- 1454846-35-5
- Unique Ingredient Identifier
- OSP71S83EU
- Background
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, fol...
- Indication
Lorlatinib is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). In the EU, it is indicated for the treatment of adult patients with ALK-positive advanced NSCLC not previously treated with an ALK inhibitor, or whose disease has progressed after using either alectinib or ceritinib, or crizotinib and ...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05740943
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05297890
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
🇨🇳Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05224609
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Genesis Clinical Research, LLC, Tampa, Florida, United States
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 118
- Registration Number
- NCT05167500
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital 12 De Octubre, Madrid, Spain
🇪🇸Hospital Clínico Santiago, Santiago De Compostela, A Coruña, Spain
Lorlatinib Continuation Study
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT05144997
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇨🇳The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Strata PATH™ (Precision Indications for Approved Therapies)
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Strata Oncology
- Target Recruit Count
- 700
- Registration Number
- NCT05097599
- Locations
- 🇺🇸
Kettering Health Network, Kettering, Ohio, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
PF-07284892 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04800822
- Locations
- 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04753658
- Locations
- 🇳🇿
Starship Blood and Cancer Centre, Auckland, New Zealand
🇵🇹Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal
🇸🇪Queen Silvia Children's Hospital, Gothenburg, Sweden
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.